Drug treatment effects on disease progression

Annual Review of Pharmacology and Toxicology

Volumn 41, Issue , 2001, Pages 625-659

  Chan, P L S ^a   Holford, N H G ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Alzheimer's; Disease progress models; Osteoporosis; Parkinson's; Protective; Symptomatic

Indexed keywords

BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; LEVODOPA; SELEGILINE; TOCOPHEROL;

ALZHEIMER DISEASE; DETERIORATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NEUROPROTECTION; PALLIATIVE THERAPY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ALZHEIMER DISEASE; ANIMALS; DISEASE PROGRESSION; DRUG THERAPY; HUMANS; OSTEOPOROSIS; PARKINSON DISEASE;

EID: 0035038023     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.41.1.625     Document Type: Review

References (148)

1. Accelerated ageing or selective neuronal loss as an important cause of dementia?
2. Normal ageing, impaired cognitive function, and senile dementia of the Alzheimer's type: A continuum?
3. Nigrostriatal function in humans studied with positron emission tomography
4. Striatal function in normal aging: Implications for Parkinson's disease
5. Does along preclinical period occur in Parkinson's disease?
6. Effect of age on the development or progression of albuminuria in noninsulin-dependent diabetes mellitus (NIDDM) without hypertension
7. Prevalence of Alzheimer's disease and vascular dementia: Association with education. The Rotterdam study
8. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM complications study
9. Prevalence of parkinsonism and Parkinson's disease in Europe: The EUROPARKINSON collaborative study
10. Risk factors for increased bone loss in an elderly population: The Rotterdam Study
11. Worldwide prevalence and incidence of dementia
12. Ageing and Parkinson's disease: Substantia nigra regional selectivity
13. Nitric oxide synthase neurons in different areas of normal aged and Alzheimer's brains
14. Age at onset and rate of progression of Alzheimer's disease
15. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
16. Inhaled beclomethasone improves the course of asthma and COPD
17. Angiotensin-converting enzyme inhibition in diabetic nephropathy: Ten years' experience
18. Tolrestat in the primary prevention of diabetic neuropathy
19. Clinical observations on the rate of progression of idiopathic parkinsonism
20. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
21. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
22. Mortality in DATATOP: A multicenter trial in early Parkinson's disease
23. Renal protective effect of enalapril in diabetic nephropathy
24. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
25. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria
26. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist
27. The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes
28. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine
29. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease
30. Positron emission tomography in degenerative disorders of the dopaminergic system
31. Clinical heterogeneity of doparesponsive dystonia: PET observations
32. Positron emission tomographic studies of aging and Alzheimer disease
33. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: Atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators
34. 123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease
35. 123I]beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease
36. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients
37. Detection of preclinical Parkinson's disease with PET
38. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data
39. Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow
40. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism
41. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease
42. 18F]fluorodopa studies correlate with dopamine cell counts and levels
43. 18F]fluorodopa positron emission tomographic studies
44. Reproducibility of fluorine-18-16-fluorodopa positron emission tomography in normal human subjects
45. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients
46. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): A dose ranging study with the reversible inhibitor Ro. 19-6327
47. 18F]-6-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease
48. Understanding the dose-effect relationship: Clinical application of pharmacokineticpharmacodynamic models
49. Heating impairment and cognitive decline in senile dementia of the Alzheimer's type
50. Rates of change of common measures of impairment in senile dementia of the Alzheimer's type
51. Longitudinal evaluation of dementia of the Alzheimer type: A comparison of 3 standardized mental status examinations
52. Progression of cognitive impairment in Alzheimer's disease
53. The consortium to establish a registry for Alzheimer's disease (CERAD). IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease
54. The rate of progression of Alzheimer's disease in the later stages: Evidence from the Severe Impairment Battery
55. Observations on the short-term "natural history" of probable Alzheimer's disease in a controlled clinical trial
56. Deterioration on the Blessed test in Alzheimer's disease: Longitudinal data and their implications for clinical trials and identification of subtypes
57. Comparison of rate of annual change of mental status score in four independent studies of patients with Alzheimer's disease
58. Dementia: Characteristics of a referral population and factors associated with progression
59. Rate of progression and prognostic factors in Alzheimer's disease: A prospective study
60. Rate of progression of Alzheimer's disease
61. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study
62. The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials
63. Population models for Alzheimer's and Parkinson's disease
64. Functional decline in Alzheimer's disease: A longitudinal study
65. Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations
66. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon
67. Pharmacodynamic modeling of oral levodopa: Clinical application in Parkinson's disease
68. Concentration-response relationship of levodopa in patients with different stages of Parkinson's disease
69. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease
70. Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients - A 3-year follow-up study
71. A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease
72. The response to levodopa in Parkinson's disease: Imposing pharmacological law and order
73. Parkinsonism: Onset, progression, and mortality
74. Disability and progression in Parkinson's disease
75. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease
76. Selegiline delays the onset of disability in de novo parkinsonian patients
77. The effect of deprenyl and levodopa on the progression of Parkinson's disease
78. 18F]dopa PET
79. 18F]DOPA PET study
80. Comparison of positron emission tomography, cognition, and brain volume in Alzheimer's disease with and without severe abnormalities of white matter
81. Premorbid brain size as a determinant of reserve capacity against intellectual decline in Alzheimer's disease
82. Rate of ventricular enlargement in dementia of the Alzheimer type correlates with rate of neuropsychological deterioration
83. Computed tomography in Alzheimer's disease: A longitudinal study
84. Longitudinal changes in lateral ventricular volume in patients with dementia of the Alzheimer type
85. Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease
86. Longitudinal volumetric computed tomographic analysis of regional brain changes in normal aging and Alzheimer's disease
87. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia
88. Brain atrophy progression measured from regisiered serial MRI: Validation and application to Alzheimer's disease
89. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease
90. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: Power calculations and estimates of sample size to detect treatment effects
91. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years
92. Mild senile dementia of the Alzheimer type. 2. Longitudinal assessment
93. The methodology of studying decline in Alzheimer's disease
94. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes
95. Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: Correlations with growth parameters
96. Distribution of forced expiratory volume in one second and forced vital capacity in healthy, white, adult never-smokers in six U.S. cities
97. Longitudinal changes in forced expiratory volume in one second in adults. Methodologic considerations and findings in healthy nonsmokers
98. Spirometric standards for healthy adult lifetime nonsmokers in Australia
99. The influence of body size, smoking, and diet on bone density in pre and postmenopausal women
100. Bone loss, physical activity, and weight change in elderly women: The Dubbo Osteoporosis Epidemiology Study
101. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women
102. Reference values and modelling of lung function development as a transcendent function of age, body height and mass
103. Longitudinal study of pulmonary function development in childhood, adolescence, and early adulthood. Development of pulmonary function
104. Spirometric standards for healthy nonsmoking adults
105. A re-evaluation of normal pulmonary function measurements in the adult female
106. Prediction values for screening tests of pulmonary function
107. The veterans administrationarmy cooperative study of pulmonary function
108. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease
109. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study
110. Two-year treatment of Alzheimer's disease with eptastigmine
111. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease
112. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?
113. A mathematical model of pathogenesis in idiopathic parkinsonism
114. Selegiline as initial treatment in de novo parkinsonian patients
115. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic
116. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial
117. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease
118. Effects of long-term treatment with corticosteroids in COPD
119. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study
120. The course of kidney function in type 2 (noninsulin-dependent) diabetic patients with diabetic nephropathy
121. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
122. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure
123. Drug treatment in postmenopausal osteoporosis
124. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss
125. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women
126. Long-term effects of calcium supplementation on bone loss on fractures in postmenopausal women: A randomized controlled trial
127. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene
128. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
129. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
130. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis
131. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
132. Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment
133. Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women
134. Effect of age at onset on progression and mortality in Parkinson's disease
135. Age at onset: The major determinant of outcome in Parkinson's disease
136. Effect of age and disease duration on parkinsonian motor scores under levodopa therapy
137. Ldopa long-term treatment in Parkinson's disease: Age-related side effects
138. Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period
139. Clinical predictors of course for Alzheimer patients in a longitudinal study: A preliminary report
140. An examination of male-female differences in progression and mortality of Parkinson's disease
141. Gender differences in Parkinson's disease
142. Multiple imputation compared with some informative dropout procedures in the estimation and comparison of rates of change in longitudinal clinical trials with dropouts
143. Clinical trial simulation - Streamlining your drug development process
144. Simulation of clinical trials
145. Computer simulation as a tool for clinical trial design
146. A simulation study comparing designs for dose ranging
147. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling